Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKB589 in Advanced Solid Tumors
NCT04632108Phase 2Active, not recruiting
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Jan 2021
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ASKB589 in solid tumor, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 1 more (4 arms), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. Primary endpoints: Number of participants with serious adverse events, Incidence and case number of Dose Limiting Toxicity and 4 more. Started Jan 2021; status: active, not recruiting.
02
Drugs
ASKB589
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04632108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632108.